Drug details

Lonhala Magnair (glycopyrrolate inhalation solution)

type of COPD Agents, Anticholinergics, Respiratory

Lonhala Magnair (glycopyrrolate) Inhalation Solution is an anticholinergic indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

The drug is often used to treat Chronic obstructive pulmonary disease .

This drug may have the following side effects:

• shortness of breath,
• upper respiratory tract infection,
• wheezing,
• urinary tract infection,
• swelling of extremities,
• runny or stuff nose,
• and fatigue.

The following drugs are related to Lonhala Magnair, either as a replacement or used together:

• Atrovent HFA (ipratropium bromide inhalation aerosol)
• Breo Ellipta (fluticasone furoate and vilanterol inhalation powder)
• Symbicort (budesonide and formoterol fumarate dihydrate)
• Symbicort Aerosphere (budesonide and formoterol fumarate inhalation aerosol)
• Relenza (zanamivir)